Management of red blood cell alloimmunization in pregnancy - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Journal of Gynecology Obstetrics and Human Reproduction Année : 2018

Management of red blood cell alloimmunization in pregnancy

Résumé

The main cause of fetal anemia is maternal red blood cell alloimmunization (AI). The search of maternal antibodies by indirect antiglobulin test allows screening for AI during pregnancy. In case of AI, fetal genotyping (for Rh-D, Rh-c, Rh-E and Kell), quantification (for anti-rhesus antibodies) and antibody titration, as well as ultrasound monitoring, are performed. This surveillance aims at screening for severe anemia before hydrops fetalis occurs. Management of severe anemia is based on intrauterine transfusion (IUT) or labor induction depending on gestational age. After intrauterine transfusion, follow-up will focus on detecting recurrence of anemia and detecting fetal brain injury. With IUT, survival of fetuses with alloimmunization is greater than 90% but 4.8% of children with at least one IUT have neurodevelopmental impairment.
Fichier non déposé

Dates et versions

hal-04491861 , version 1 (06-03-2024)

Identifiants

Citer

Louise Ghesquière, Charles Garabedian, Capucine Coulon, P. Verpillat, Thameur Rakza, et al.. Management of red blood cell alloimmunization in pregnancy. Journal of Gynecology Obstetrics and Human Reproduction, 2018, Journal of gynecology obstetrics and human reproduction, 47 (5), pp.197-204. ⟨10.1016/j.jogoh.2018.02.001⟩. ⟨hal-04491861⟩

Collections

UNIV-LILLE
1 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More